CytomX Therapeutics (CTMX)

• Market cap: $336M
• 1 day: 2.00%
• 5 days: 1.49%
• 1 month: -14.64%
• 3 months: -4.23%
• 6 months: 199.47%
• Year to date: 92.45%
• 1 year: 71.43%
• 5 years: -70.98%
• 10 years: -84.19%
• Sector: Healthcare
• Industry: Biotechnology

About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Employees: 121

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

948% more capital invested

Capital invested by funds: $28.8M [Q1] → $302M (+$273M) [Q2]

524% more call options, than puts

Call options by funds: $2.05M | Put options by funds: $328K

142% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 12

108.46% more ownership

Funds ownership: 56.52% [Q1] → 164.98% (+108.46%) [Q2]

47% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 17

24% more funds holding

Funds holding: 66 [Q1] → 82 (+16) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 243% upside
• Avg. target: $7 243% upside
• High target: $7 243% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Matthew Biegler

243% upside $7

Outperform Initiated

31 Jul 2025